Article
Medicine, General & Internal
Zhipeng Du, Zhongchao Zhang, Xu Han, Huaping Xie, Wei Yan, Dean Tian, Mei Liu, Caijun Rao
Summary: This study reveals the upregulation of SFXN4 in hepatocellular carcinoma (HCC) and its correlation with poor prognosis. SFXN4 is associated with oxidative phosphorylation, metabolic pathways, and several cancer-related pathways. It is regulated by multiple transcription factors and miRNAs. Knockdown of SFXN4 inhibits HCC proliferation, migration, and invasion in vitro, and suppresses tumor growth in vivo.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Shushu Song, Yinghong Shi, Weicheng Wu, Hao Wu, Lei Chang, Peike Peng, Lei Zhang, Jia Fan, Jianxin Gu, Yuanyuan Ruan
Summary: Dysfunction of ER proteins is closely related to HCC development. RTN3 is expressed in normal hepatocytes but downregulated in HCC, predicting poor outcomes in patients with certain gene mutations or infections. RTN3 functions as a suppressor of HCC by activating the Chk2/p53 pathway, but its effects are abrogated in HBV-positive cells.
Article
Oncology
Yunzheng Li, Binghua Li, Yanchao Xu, Liyuan Qian, Tiancheng Xu, Gang Meng, Huan Li, Ye Wang, Laizhu Zhang, Xiang Jiang, Qi Liu, Yuanyuan Xie, Chunxiao Cheng, Beicheng Sun, Decai Yu
Summary: The study reveals that low expression of GOT2 is associated with advanced progression and poor prognosis of HCC. Knock down of GOT2 promotes proliferation, migration, and invasion of HCC cells, and loss of GOT2 promotes tumor growth and metastasis in mouse models. Mechanistically, silencing of GOT2 reprograms glutamine metabolism to support the cellular antioxidant system and activates the PI3K/AKT/mTOR pathway, promoting HCC progression. HCC with low expression of GOT2 is highly sensitive to the glutaminase inhibitor CB-839.
Article
Pharmacology & Pharmacy
Jisoo Song, Jiyeon Ham, Taeyeon Hong, Gwonhwa Song, Whasun Lim
Summary: Fraxetin extracted from Fraxinus rhynchophylla shows anticancer effects in hepatocellular carcinoma (HCC) cells by inhibiting cell proliferation, inducing apoptosis, and disrupting cellular environments. It has the potential to be a therapeutic agent against HCC progression.
Article
Oncology
Shangbiao Li, Simiao Qiao, Na Li, Xiaoxia Zhu
Summary: MiR-744 plays a key role in the development of non-small cell lung cancer (NSCLC) by up-regulating c-Fos through binding to its promoter, thereby promoting the malignant phenotype of the disease. The findings highlight the potential value of miR-744 as a therapeutic target for NSCLC.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Haiyuan Li, Lei Gao, Xiaojuan Kang, Xueyan Wang, Yang Yu, Yaqing Zhang, Hao Chen
Summary: This study explored the expression and function of 40S ribosomal protein S24 (RPS24) in hepatocellular carcinoma (HCC). Results showed that RPS24 was elevated in HCC samples and related to poor prognosis. Furthermore, RPS24 overexpression or promoter methylation correlated with unfavorable prognosis in HCC patients. High expression of RPS24 was associated with DNA replication, cell cycle, immune infiltration, and immunotherapy response. Experimental validation demonstrated that silencing of RPS24 suppressed HCC cell growth and tumor proliferation. Therefore, RPS24 may serve as a potential adverse biomarker for HCC prognosis, acting through cell proliferation facilitation and the formation of an immunosuppressive microenvironment, and targeting RPS24 could be a promising therapeutic option for HCC management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Qingqing Dai, Quratul Ain, Michael Rooney, Fei Song, Alexander Zipprich
Summary: IQGAPs are a class of proteins that regulate cellular activities by controlling cytoskeletal remodeling and cellular signal transduction. In hepatocellular carcinoma, IQGAP1 and 3 are upregulated and considered oncogenes, while IQGAP2 is downregulated and acts as a tumor suppressor. This review provides a detailed overview of the structure, expression, and role of IQGAPs in liver diseases and hepatocellular carcinoma, serving as a reference for further research.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Liping Sun, Shuguang Liu, Xiaopai Wang, Xuefeng Zheng, Ya Chen, Hong Shen
Summary: The study demonstrated that eIF6 expression was significantly increased in HCC and correlated with its pathological progression. eIF6 served as a new diagnostic biomarker and an independent risk factor for OS in HCC patients. Functional studies showed that deletion of eIF6 exhibited tumor-suppressor activity in HCC cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Shijie Qin, Jieyun Xu, Yunmeng Yi, Sizhu Jiang, Ping Jin, Xinyi Xia, Fei Ma
Summary: The study identified 114 dysregulated mature miRNAs in HCC, primarily influenced by dysregulated transcription factors or DNA methylation. Several up-regulated miRNAs were shown to promote tumorigenesis by inhibiting tumor suppressor genes, while down-regulated miRNAs suppress abnormal cell proliferation by inhibiting oncogenes. The interplay between transcription factors and miRNAs plays a significant role in the occurrence and development of HCC, and the transcription factor FOXO1 may be an effective therapeutic target for improving the survival of HCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Jiasheng Lei, Shuoshuo Ma, Wanliang Sun, Dongdong Wang, Zheng Lu, Dengyong Zhang
Summary: In this study, the researchers found that H2AFY is highly expressed in liver cancer cells and tissues. H2AFY promotes the proliferation and clone formation of liver cancer cells, but has no significant effects on cell migration and invasion. The study suggests that H2AFY could be a potential target for liver cancer therapy.
Review
Oncology
Hewen Shi, Ying Zou, Weiwei Zhong, Zhaoying Li, Xiaoxue Wang, Yancun Yin, Defang Li, Ying Liu, Minjing Li
Summary: This review summarizes the important roles of Yap/Taz in activating the Hippo pathway in liver cancer, and discusses the crosstalks between the Hippo pathway and other cancer associated pathways and molecules.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lin Cai, Yu Du, Kai Song, Peng Peng, Fei Han
Summary: The study found that transmembrane protein 88 (TMEM88) is negatively correlated with the progression of hepatocellular carcinoma (HCC), and higher levels of TMEM88 can predict better survival rates in HCC patients. In cell and animal models, overexpression of TMEM88 inhibits the growth of HCC.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jessica Oyie Sousa Onyeisi, Carla Cristina Lopes, Martin Goette
Summary: Syndecan-4 plays crucial roles in cell behavior and interactions with growth factors, extracellular matrix molecules, and signaling proteins in various cancers. The expression level of syndecan-4 is important for understanding malignant transformation and it emerges as a target for cancer therapy and diagnosis.
Article
Multidisciplinary Sciences
Qing Tong, Dong Yan, Yan Cao, Xiaogang Dong, Yimamumaimaitijiang Abula, Huan Yang, Panpan Kong, Mingyu Yi
Summary: NVS-ZP7-4, a novel chemical reagent targeting ZIP7, shows anti-tumor effects on HCC by inhibiting cell proliferation, migration, and invasion, and the activation of PI3K/AKT pathway. It serves as a promising therapeutic target for HCC.
SCIENTIFIC REPORTS
(2023)
Article
Biotechnology & Applied Microbiology
Xiuli Jin, Weixin Fu, Dan Li, Ningning Wang, Jiayu Chen, Zilu Zeng, Jiaqi Guo, Hao Liu, Xinping Zhong, Hu Peng, Xin Yu, Jing Sun, Xinhe Zhang, Xue Wang, Beibei Xu, Yingbo Lin, Jianping Liu, Claudia Kutter, Yiling Li
Summary: The abnormal high expression of LINC01268 is associated with HCC progression through regulating MAP3K7, indicating LINC01268 as a potential novel marker for HCC prognosis and a new therapeutic target. The study found that LINC01268 was highly expressed in HCC cell lines and tissues, and its knockdown inhibited cell proliferation while overexpression enhanced it. Co-expression analysis suggested an interaction between LINC01268 and MAP3K7, highlighting their role in HCC development.
ONCOTARGETS AND THERAPY
(2021)